Diving Into the Complement Cascade to Explore Intervention Points, Harnessing Biomarker Strategies to Identify Optimal Patient Populations, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. So far, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis, Annexon Biosciences and Omeros, are making […]

Recognized as the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda, Arsenal Bio, Bayer, Genentech, Adicet Bio, Quell Therapeutics, and […]

The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself, in what jobs, with what skills, and across what proportion of our workforces is not yet fully clear. What is clear, […]

Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell […]

RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, […]

The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore […]

The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. Don't miss this pivotal opportunity […]

With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes, new FDA draft guidance on post-approval CMC, and potency assays facing heightened scrutiny, the environment is rapidly evolving. Global efforts to align […]

Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from strength to strength. With a surge of billion-dollar investments, the release of new groundbreaking data, and recent real-world clinical progression, the autoimmune cell therapy field is […]

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to […]

As biopharma organizations decrease their budgets and move away from a recruitment-centric approach, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. This December in Boston, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support […]

With the launch of the FDA’s Project Optimus, and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. Bringing together a focused audience of clinical pharmacology, PK, pharmacometrics, modelling, and bioanalysis specialists, the 2nd ADC Pharmacokinetics & Clinical Pharmacology […]

Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches. Join 100+ […]